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Computed tomographyThe effects of an active vitamin D analog, eldecalcitol (ELD), on bone mineral density (BMD), bone geometry,
and biomechanical properties of the proximal femur were investigated by using clinical CT. The subjects – a
subgroup of a recent randomized, double-blind study comparing anti-fracture efﬁcacy of ELDwith alfacalcidol
(ALF) – constituted 193 ambulatory patients with osteoporosis (189 postmenopausal women and 4men aged
52–85 years, average±SD: 70.9±6.92 years) enrolled at 11 institutions. Multidetector-row CT data was
acquired at baseline and at completion of 144 weeks' treatment. Cross-sectional densitometric and geometric
parameters of the femoral neck were derived from three-dimensional CT data. Biomechanical properties
including cross-sectional moment of inertia (CSMI), section modulus (SM) and buckling ratio (BR) of the
femoral neck, and CSMI of the femoral shaft were also calculated. We found that, 1) with respect to the
femoral neck cross-sectional parameters (total bone), in the ALF group, volumetric BMD (vBMD) decreased
but bone mass was maintained and cross-sectional area (CSA) increased. In contrast, ELD maintained vBMD
with a signiﬁcant increase in bonemass and a trend toward increased CSA. 2)With respect to the femoral neck
cross-sectional parameters (cortex), cortical thickness decreased in the ALF group, but was maintained in the
ELD group. In the ALF group, vBMD and bone mass increased, and CSA was maintained. In the ELD group,
vBMD, CSA, and bone mass increased. 3) With respect to the biomechanical properties of the femoral neck,
ELD improved CSMI and SM to a greater extent than did ALF. BR increased in both the ALF and ELD groups.
4) With respect to the femoral shaft parameters, overall the results of bone geometry and CSMI of the femoral
shaft were very consistent with the results for the femoral neck; however, cortical vBMD of the femoral shaft
decreased signiﬁcantly in both the ELD and ALF groups. In conclusion, our longitudinal analysis of hip
geometry by clinical CT revealed the unexpected potential of ELD to increase cortical CSA, vBMD, and bone
mass, and to maintain cortical thickness, probably through the more potent effect of ELD in mitigating
endocortical bone resorption than ALF. By improving the biomechanical properties of the proximal femur, ELD
may have the potential to reduce the risk of hip fractures., toshinak@med.uoeh-u.ac.jp
ukunaga),
okushima-u.ac.jp
-NC-ND license.© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The incidence of vertebral fracture increases linearly with aging and
is signiﬁcantly correlated with declining bone mineral density (BMD).
The incidence ofhip fracture, on theother hand, rises exponentiallywith
aging, suggesting that age-related factors other than BMD contribute
greatly to the fragility of the proximal femur. Hip fractures cause
substantial disability and are associatedwith a high rate of death amongelderly women [1]. Because vertebral fracture is the most common of
osteoporotic fractures, the efﬁcacy of anti-osteoporotic agents is judged
in clinical trials by evaluating the incidence of vertebral fracture.
The incidence of hip fracture is much lower than that of vertebral
fracture, especially in elderly Japanese, and in clinical trials of anti-
osteoporotic agents hip fracture is assessed as a secondary endpoint or
as one of the non-vertebral fractures. However, in viewof the increasing
incidence of hip fracture in the Japanese population [2] and its
consequences of seriously reducing quality of life (QOL) [3], measures
to prevent hip fracture are of paramount importance.
Recently, various imaging techniques have been used to non-
invasively estimate the effects of intervention on the biomechanical
properties of the proximal femur [4]. Both the structural and biomechan-
ical propertiesof theproximal femur are critically determinedby thebone
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[5]. However, the complex structure and bone density distribution in this
region make three-dimensional (3D) analysis of the proximal femur
difﬁcult.
One clinically useful approach for assessing BMD and bone
geometry is hip structure analysis (HSA) [6] based on dual-energy
X-ray absorptiometry (DXA) data and biomechanical indices [7].
However, because most of the geometrical parameters of HSA depend
on assumptions about the shape of the cross-section and on ﬁxed
percentages of cortical bone, and because all of the geometrical
parameters are derived from bone density [8], DXA-based HSA does
not provide the actual 3D information. Nevertheless, several studies
have employed HSA to examine the longitudinal effects of anti-
osteoporotic agents [9–12]. Furthermore, poor accuracy and precision
of hip DXAmeasurement is inevitable in cases where the femoral neck
is short and in cases where it is difﬁcult to maintain the inner rotation
of the hip joint [13]. Computed tomography (CT) measurement, on
the other hand, is convenient and useful in that the femoral
dimensions can be adjusted during image processing.
Quantitative computed tomography (QCT) has become an in-
creasingly useful clinical research tool for measuring volumetric BMD
(vBMD) and analyzing hip geometry [14–17]. CT-based HSA provides
geometrical parameters independent of BMD, and has the advantage
of being able to evaluate the cortex separately. However, only one
study has employed CT to examine the effects of drugs on the 3D
geometrical parameters of the proximal hip [18].
Eldecalcitol (ELD) is a vitamin D analog that has a hydroxypropoxy
substituent at the 2β-position of 1,25-dihydroxyvitamin D3. In a phase
II randomized, placebo-controlled, double-blind clinical trial for
osteoporotic subjects with sufﬁcient vitamin D supply, ELD treatment
for 12 months signiﬁcantly increased BMD of the lumbar spine and
hip in a dose-dependent manner [19]. Further, a recent phase III
randomized, active comparator, double blind study to compare the
effects of 144 weeks' ELD treatment and 144 weeks' alfacalcidol (ALF)
treatment on osteoporotic fracture has demonstrated the superior
anti-fracture efﬁcacy of ELD [20]. The clinical effect of ALF in
preventing vertebral fractures has been reported [21]. Although the
effects of ALF on bone geometry and strength of the proximal femur
have not been established in humans, the effects of ALF on cortical
bone have been reported in animal studies using ovariectomized or
aged rats [22,23].
The purpose of the present study is to evaluate the effects of ELD
versus ALF on BMD, bone geometry, and biomechanical properties of
the proximal femur by using clinical multidetector-row CT (MDCT) in
a subgroup of the phase III randomized clinical trial, and to identify
structural features peculiar to ELD action.
Subjects and methods
Subjects
The subjects were 193 ambulatory patients with osteoporosis
(189 postmenopausal women and 4 men; age range: 52–85 years,
average±SD: 70.9±6.92 years), who represent a subgroup of a
randomized, active comparator, double-blind study to compare the
anti-fracture efﬁcacy of ELD with that of ALF in 1054 subjects (1030
women and 24 men, aged from 46 to 92 years, mean age: 72.1 years)
enrolled at 52medical centers in Japan [20]. In that study, subjects were
randomly assigned to receive either 0.75 μg ELD or 1.0 μg ALF once daily
for 144 weeks. This trial is registered with ClinicalTrials.gov, number
NCT00144456. The protocol was approved by the internal human
studies review board at each center, and written informed consent was
obtained from each patient.
The proximal femur of the 193 subjectswas scannedwithMDCT at 11
institutions to measure hip BMD, bone geometry, and biomechanical
indices.Wedidnot intentionally select the subjects. Sincenot all instituteshad anMDCT scanner, the 193 subjectswere those examined and treated
in hospitals which had MDCT scanners. All subjects in this study fulﬁlled
the inclusion criteria of the original study. In brief, in the original study,
subjectswithout vertebral fractureswere enrolled if their lumbar spine or
total hip BMD T-score was below−2.6 and theywere over 70 years, or if
their T-score was below −3.4 and they were below 70 years. Patients
with lumbar spine or total hip BMD T-score of below−1.7were enrolled
if they had between one and ﬁve vertebral fractures. Prevalent vertebral
fractures at enrolment were assessed by lateral spine X-ray examination
of the thoracic and lumbar vertebrae, and were diagnosed quantitatively
according to the criteria of the Japanese Society for Bone and Mineral
Research (JSBMR) [24]. Womenwere at least 3 years after menopause or
more than 60 years of age. Patients were excluded if they had primary
hyperparathyroidism, Cushing's syndrome, prematuremenopause due to
hypothalamic, pituitary or gonadal insufﬁciency, poorly controlled
diabetes mellitus (HbA1c over 9%) or other causes of secondary
osteoporosis, or had a history of urolithiasis. Patients were also excluded
if they had taken any oral bisphosphonates within 6 months before entry
or for more than 2 weeks during the period 6 to 12 months before entry,
or intravenous bisphosphonates at any time; had taken glucocorticoids,
calcitonin, vitamin K, active vitamin D compounds, raloxifene, or
hormone replacement therapy within the previous 2 months; had
serumCa levels of above10.4 mg/dL (2.6 mmol/L) or urinaryCa excretion
of over 0.4 mg/dL glomerular ﬁltrate (GF)(0.1 mmol/L GF); had serum
creatinine above 1.3 mg/dL (115 μmol/L); or had clinically signiﬁcant
hepatic or cardiac disorders.
Methods
CT data acquisition
CT data was acquired at baseline and at completion of 144 weeks of
treatment, using the following scanning and reconstruction protocol.
The scanning conditions (X-ray energy: 120–140 kV; X-ray current:
200–300 mA; rotation speed: 0.8–1.0 s/rot; beam pitch: 0.5625–
0.9375) and reconstruction parameters were predeﬁned for each type
of CT scanner (see Appendix). Beam pitch is deﬁned as the ratio of table
feed per rotation to the collimation, where collimation is the product of
slice-thickness and the number of slices in each rotation. Beam pitch
was kept under 1.0 except for one CT scanner (Somatom Plus 4 Volume
Zoom). Field of View (FOV) was deﬁned as 350 mm to cover both hip
regions. In-plane spatial resolution of 0.625–0.652 mm and recon-
structed slice thickness of 0.500–0.625 mm was adjusted according to
CT scanner type (see Appendix). The CT values were converted to bone
mineral scale by using a solid reference phantom, B-MAS200 (Fujirebio
Inc., Tokyo, Japan), containing hydroxyapatite (HA) at 0, 50, 100, 150,
and 200 mg/cm3. For all of the CT data, a constant threshold value of
350 mg/cm3 was used to deﬁne the cortical bone.
The MDCT scanners used in this study originally included four
Asteion 4 scanners, one Aquilion 4 scanner, and three Aquilion 16
scanners (Toshiba Medical Systems Corporation,Tochigi, Japan);
one LightSpeed Ultra_8 scanner, and one LightSpeed Plus_4 scanner
(GE-YokogawaMedical,Tokyo,Japan); and one Somatom Plus 4 Volume
Zoom scanner (Siemens, AG, Berlin and Munich, Germany). In two
institutions, CT scanners were changed during the trial period (from
Aquilion 16 to Aquilion 64, and from LightSpeed Plus_4 to LightSpeed
Ultra_16); therefore, the pairs of CT data in 26 patients were obtained
using different CT scanners. However, because the results of all patients
did not differ from results excluding the 26 patients (data not shown),
the results of all patients are presented in this article.
Good linear correlations between the CT values and HA concentra-
tions were demonstrated (r=0.996–0.999; pb0.0002–0.05) in all CT
scanners. Differences in CT values according to X-ray energy were
corrected by using the reference phantom to convert CT values to HA
equivalent values. However, it was necessary to conﬁrm the longitudi-
nal stability of the CT values of the threshold value used to deﬁne the
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was used as the threshold value to deﬁne the cortical region, there was
less than 0.01% difference between the baseline CT value and CT value at
144 weeks.
Positioning of patients for CT scanning
The subjectswere scanned in the supine position,with the reference
phantombeneath the patient and placed so as to cover a region from the
top of the acetabulum to 5 cmbelow the bottomof the lesser trochanter
in each hip joint (average slice number was 298). Bolus bags were
placed between the subject and the CT calibration phantom. Both feet
were ﬁxed using a custom-made adjuster for hip DXA, which kept the
subject's kneesﬂat and the toes pointed inward. The subject's hands and
armswere placed over the subject's head or as high on the chest as was
comfortable to avoid interferingwith the scan area. The CT scanner table
height was set to the center of the greater trochanter.
Analysis of BMD, bone geometry, and biomechanical properties obtained
by CT
Analysis of CT data
Patient data were evaluated with QCT-Pro software v4.1.3 with the
QCT-Pro Bone Investigational Toolkit v2.0 (BIT) (Mindways Software,
Austin,USA) and also with Real Intage visualization software (KGT,
Tokyo,Japan) based on 3D DICOMdata to provide fusion functions and
several geometrical measurements. All measurements were analyzed
by a radiologist (M. Ito) blinded to treatment group assignment.
QCT-Pro CTXAhip examanalysis.The exact 3D rotation of the femur and
the threshold setting for deﬁning the bone contours appeared to be
the two most critical steps for achieving accuracy and reproducibility
in the automated procedures performed by QCT-Pro. The outer
cortical BMD thresholds had to be adapted individually for each scan.
The femoral neck axis was identiﬁed visually and also automat-
ically with the “Optimize FN Axis” algorithm. QCT-Pro BIT processing
was then performed with a ﬁxed bone threshold for cortical
separation set to 350 mg/cm3 for all patients and visits.
This applicationwas used tomeasure hip axis length (HAL), femoral
neck angle (FNA), and neck width. vBMD, cross-sectional area (CSA),
and cross-sectional bone mass of the femoral neck (total, cortical, and
trabecular region), as well as cortical thickness and cortical perimeter
were also measured. Trabecular parameters in each subject were
calculated based on the total and cortical parameters. Biomechanical
properties were also derived from the cross-sectional parameters of the
femoral neck.
Real Intage analysis. This comprehensive image data visualization
software based on 3DDICOMdata provides fusion functions and several
geometrical measurements. For bone analysis of the femoral shaft, this
software was used for fusion of 3D images from baseline and images at
144 weeks to deﬁne the same regions of interest. The softwarewas then
used to measure the outer perimeter, inner perimeter, bone area,
cortical bone density, and cross-sectional moment of inertia (CSMI) of
the femoral shaft.
Analysis of cross-sectional volumetric BMD and bone geometry of the
femoral neck
The cross-sectional femoral neck datawere derived on the basis of the
geometrical axis to calculate volumetric total BMD(total vBMD;mg/cm3),
cortical BMD (cortical vBMD; mg/cm3), trabecular BMD (trabecular
vBMD; mg/cm3), total CSA (cm2), cortical CSA (cm2), trabecular CSA
(cm2), total bone mass (g), cortical bone mass (g), and trabecular bone
mass (g). Cortical thickness (mm) and cortical perimeter (mm)were also
derived.
These parameters were all calculated with QCT-Pro.Biomechanical parameters of the femoral neck
Because biomechanical parameters were determined on the
principal axis, the cross-sectional moment of inertia (CSMI; mm4), the
section modulus (SM; mm3), and buckling ratio (BR) were calculated
from bone density and geometrical data. The CSMI is deﬁned by the
integration of products of incremental cross-sectional area and the
square of their distance fromthe center ofmass (centroid). TheSM is the
ratio of CSMI to the maximal distance of thematerial from the centroid,
which is directly related to the strengthwith respect to a corresponding
bending stress. For very thin-walled bones, failure occurs on the
compressive surface due to local buckling,which is estimated as BR; this
was calculated in this study as the average distance from the centroid
divided by the average cortical thickness.
These parameters were calculated with QCT-Pro.
Analysis of vBMD, bone geometry, and biomechanical properties of the
femoral shaft
Using the Real Intage program, image fusionwasperformedbetween
the baseline image and image at 144 weeks to adjust the regions for
analyses. vBMD and geometry were calculated in the region of the
femoral shaft from 2 to 4 cm below the bottom of the lesser trochanter.
The threshold value todiscriminate thecortical regionwasdeﬁnedas the
CT value corresponding to 200 mg/cm3 HA in the reference phantom. In
the femoral shaft, average cortical density (Co.vBMD; mg/cm3), total
area (T.AR; mm2), bone area (B.AR; mm2), cortical outer perimeter
(OUT.PERI; mm), cortical inner perimeter (INN.PERI; mm), and cross-
sectional moment of inertia (CSMI; mm4) were measured.
Reproducibility of the analysis by the QCT-Pro program was
calculated by using ﬁve repeated measurements with visual matching
each time from CT data sets without visible artifacts from seven
healthy subjects. The coefﬁcient of variation (%), as determined by the
root mean square standard deviation divided by the mean, was 1.49%
for total vBMD, 2.63% for cortical vBMD, 1.12% for total mass, 1.71% for
total area, 2.11% for cortical area, 2.11% for cortical perimeter, and
3.58% for cortical thickness in the femoral neck [25]. In the analysis of
the femoral shaft using Real Intage, the coefﬁcient of variation was
0.53% for cortical vBMD, 0.52% for total area, 0.80% for bone area,
1.52% for outer perimeter, and 2.22% for inner perimeter. Since the %
CVs of the others were similar, we did not present them all.
Statistics
All randomized patients who had been administered one of the
drugs and who had been assessed both at baseline and at 144 weeks
were included in the analysis.
Student's t-tests were used to determine the signiﬁcance of
differences between the ALF and ELD groups. Paired t-tests were
used to determine the signiﬁcance of difference from the baseline.
All p values calculated in the analysis were two-sided and were not
adjusted for multiple testing. A p value of less than 0.05 was considered
to indicate statistical signiﬁcance.
Statistical analyses were done with SAS version 8.2 (SAS Institute,
Cary USA).
Results
Table 1 shows the demographic and bone characteristics of the
subjects at baseline. None of the parameters differed signiﬁcantly
between the ALF and ELD groups.
Cross-sectional geometry and vBMD of the femoral neck
In the femoral neck, we measured cross-sectional cortical thickness
and perimeter, as well as the total, cortical, and trabecular vBMD, CSA,
and bonemass (Fig. 1). Cortical thickness of the femoral neck decreased
signiﬁcantly from baseline in the ALF group (−4.54±7.72%, pb0.001),
Table 1
Baseline demographics and bone characteristics of patients in the alfacalcidol and
eldecalcitol groups.
Eldecalcitol
(n=100)
Alfacalcidol
(n=93)
Age (years) 71.2±7.05 70.6±6.80
Body height (cm) 149.9±6.17 148.8±5.53
Body mass index (kg/m2) 22.0±2.65 22.3±3.20
Years since menopause (years) 20.9±7.54 21.7±8.23
Number of prevalent vertebral fractures 1.2±1.17 1.3±1.39
Bonemineral density by DXA (T score)
Total hip −2.21±0.79 −2.15±0.90
Lumbar spine −2.81±0.90 −2.72±0.83
Bone biomarker
Serum bone-speciﬁc alkaline
phosphatase (U/L)
32.9±11.1 33.3±12.8
Urinary type I collagen
N-telopeptide (nmol BCE/mmol Cr)
58.6±29.8 62.6±34.8
Ca intake (mg/day) 760±355.4 783±326.8
Serum 25(OH)D (CLIA) (ng/mL) 23.1±7.08 22.0±5.84
QCT geometric parameters
Femoral neck axis angle (°) 40.43±10.67 38.20±16.60
Femoral neck width (mm) 24.83±2.24 24.91±2.33
Hip axis length (mm) 104.83±6.29 104.01±6.47
Femoral neck BMD/cross-sectional
geometry
Total vBMD (g/cm3) 303.0±62.14 295.1±53.61
Total CSA (cm2) 5.37±0.784 5.40±0.831
Cortical vBMD (g/cm3) 692.4±66.79 693.9±56.03
Cortical CSA (cm2) 1.65±0.240 1.65±0.278
Cortical thickness (mm) 1.50±0.302 1.49±0.312
Perimeter (mm) 97.2±9.42 96.4±10.39
Femoral shaft BMD/cross-sectional geometry
Cortical vBMD (g/cm3) 1373.1±195.83 1369.2±193.25
Tissue area (cm2) 614.1±61.87 611.8±73.66
Bone area (cm2) 475.5±41.30 474.2±51.37
Outer perimeter (mm) 90.0±4.64 89.7±5.70
Inner perimeter (mm) 43.0±6.01 42.9±6.68
Biomechanical property
Neck cross-sectional moment
of inertia (cm4)
0.520±0.158 0.51±0.140
Section modulus 0.38±0.100 0.38±0.097
Buckling ratio 9.16±2.424 9.17±2.230
Shaft cross-sectional moment
of inertia (cm4)
52986.4±10234.22 52651.8±13264.96
Values are mean±standard deviation.
vBMD: volumetric bone mineral density, CSA: cross-sectional area.
nmol BCE/mmol Cr: nmol Bone Collagen Equivalent/mmol Creatinine.
CLIA: Chemiluminescence immunoassay.
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Fig. 1. Eldecalcitol maintains cortical thickness and increases volumetric BMD and bone
mass in cortex of femoral neck. Values are percentage changes frombaseline (mean±SD)
in cross-sectional bone geometry and vBMD in the femoral neck for groups treated with
alfacalcidol (blue bars) and eldecalcitol (red bars). *pb0.05, **pb0.01, ***pb0.001. vBMD:
volumetric bone mineral density. CSA: cross-sectional area.
331M. Ito et al. / Bone 49 (2011) 328–334while it did not signiﬁcantly change in the ELD group; as a result, the
percentage change in cortical thickness differed signiﬁcantly between
the ELD and ALF groups (p=0.042). Cortical perimeter increased
signiﬁcantly from baseline in both the ELD group (2.63±7.52%,
p=0.008) and the ALF group (3.86±6.28%, pb0.001). Thus, although
there was no signiﬁcant difference between the effects of the two drugs
on the increased cortical perimeter, ELD prevented the decrease in
cortical thickness.
Cortical vBMD of the femoral neck increased signiﬁcantly in both
the ELD group (1.82±4.78%, p=0.004) and the ALF group (2.21±
4.98%, pb0.001), with no difference between the two groups (Fig. 1).
Trabecular vBMD of the femoral neck signiﬁcantly decreased in both
the ALF group (−7.49±8.82%, pb0.001) and the ELD group (−3.99±
7.83%, pb0.001), and there was a signiﬁcant difference between the
two groups (p=0.020). Total vBMD of the femoral neck decreased
from baseline in the ALF group (−2.25±5.32%, pb0.001), whereas it
was maintained in the ELD group. Accordingly, the percentage
changes in total vBMD differed signiﬁcantly between the ELD and
ALF groups (p=0.009).
Regarding cortical CSA, the ELD group showed a non-signiﬁcant
trend for an increase (1.73±7.62%, p=0.082) and the ALF group
showed a non-signiﬁcant trend for a decrease (−0.96±6.14%,
p=0.212) (Fig. 1). Thus, the percentage changes from the baseline incortical CSA showed a signiﬁcant difference between the ELD and ALF
groups (p=0.031). Trabecular CSA of the femoral neck increased
signiﬁcantly in the ALF group (2.92±7.74, p=0.003), but not in the ELD
group (1.92±7.61%, p=0.054). Total CSA increased from the baseline in
both the ELD group (1.69±6.78%, p=0.056) and the ALF group (1.51±
5.77%, p=0.039), with no difference between the two groups.
Cortical bone mass of the femoral neck increased signiﬁcantly from
baseline in both the ELD group (3.68±7.51%, pb0.001) and the ALF
group (2.45±9.64%, p=0.045) (Fig. 1). Total bone mass of the femoral
neck increased signiﬁcantly only in the ELD group (1.93±5.89,
p=0.013). Trabecular bone mass signiﬁcantly decreased in the ALF
group (−3.96±9.39, pb0.001),whereas it did not change frombaseline
in the ELD group, and there was no signiﬁcant difference between the
two groups (p=0.268). Thus, in the ELD group, both total and cortical
bone mass increased from baseline, and trabecular bone mass was
maintained.
Biomechanical properties of the femoral neck
Biomechanical properties (CSMI, SM, and BR) of the femoral neck
were compared between the ELD group and the ALF group (Fig. 2).
CSMI and SM improved signiﬁcantly in the ELD group (5.30±11.56%,
pb0.001 for CSMI; 4.33±11.92%, p=0.006 for SM), whereas these
parameters did not change in the ALF group. Thus, there were
signiﬁcant differences between the ELD and ALF groups in the
percentage changes of CSMI and SM from baseline (p=0.037 and
p=0.023, respectively). Although BR increased from the baseline in
both treatment groups (3.76±11.33%, p=0.012 in ELD; 7.44±9.43%,
pb0.001 in ALF), the increase was signiﬁcantly less in the ELD group
than in the ALF group (p=0.049) (Fig. 2). Collectively, these results
suggest that ELD maintained the biomechanical properties of the
femoral neck more effectively.
Geometry, vBMD, and biomechanical properties of the femoral shaft
The percentage changes in BMD, bone geometry, and biomechanical
properties in the femoral shaft were compared between the ELD
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Fig. 2. Eldecalcitol improves biomechanical properties of the femoral neck. Cross-sectional
moment of inertia (CSMI), sectionmodulus (SM), and buckling ratio (BR)were calculated
in the femoral neck, and percentage changes frombaseline (mean±SD) are shown for the
alfacalcidol group (blue bars) and the eldecalcitol group (red bars). *pb0.05, **pb0.01,
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332 M. Ito et al. / Bone 49 (2011) 328–334group and the ALF group (Fig. 3). Cortical vBMD in the shaft decreased
signiﬁcantly in both the ELD group (−10.13±4.54%, pb0.001) and the
ALFgroup (−11.85±4.58%, pb0.001) (Fig. 3); however, thepercentage
decrease was signiﬁcantly smaller in the ELD group than in the ALF
group (p=0.026). Although the total area increased signiﬁcantly from
baseline in both the ELD and ALF groups, the bone area of the femoral
shaft increased signiﬁcantly only in the ELD group (1.75±3.24%,
pb0.001).
Outer perimeter increased signiﬁcantly from baseline in both
treatment groups (0.92±1.67%, pb0.001 in ELD; 0.94±2.22%,
pb0.001 in ALF), with no difference between the two groups. Inner
perimeter increased signiﬁcantly in both groups (0.76±2.75%,
p=0.023 in ELD; 1.85±3.52%, pb0.001 in ALF); however, the
percentage increase was signiﬁcantly greater in the ALF group than0
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Fig. 3. Effects of eldecalcitol on bone geometry and biomechanical properties of the
femoral shaft. Percentage changes from baseline (mean±SD) in vBMD, bone geometry,
and biomechanical properties in the femoral shaft are shown for the alfacalcidol group
(blue bars) and the eldecalcitol group (red bars). Co.vBMD: cortical volumetric bone
mineral density; T.AR: total area; B.AR: bone area; OUT.PERI: outer perimeter; INN.PERI:
inner perimeter; CSMI: cross-sectional moment of inertia. *pb0.05, **pb0.01, ***pb0.001.in the ELD group (p=0.042). CSMI in the femoral shaft increased
signiﬁcantly from baseline in both the ELD and ALF groups. Thus,
although there was no difference between groups with respect to this
biomechanical parameter, the increase in inner perimeter, presum-
ably due to accelerated resorption, was more effectively prevented by
ELD.Discussion
A recent randomized, double-blind study to compare the effects of
ELD with ALF demonstrated the superiority of ELD over the active
comparator, especially with respect to non-vertebral fractures [20]. In
order to gain insight into the biomechanical basis underlying this
clinically veriﬁed anti-fracture action of ELD, we took a subgroup of
the randomized study and used clinical MDCT scanning to compare
the effects of ELD and ALF on the 3D structure of the proximal femur,
focusing particularly on the cortical component and biomechanical
properties. Our study not only revealed the distinct action of ELD on
the cortical compartment but also provided evidence for the
improvement of biomechanical properties.
In the femoral neck, whereas cross-sectional cortical thickness
decreased in the ALF group, it wasmaintained in the ELD group. Taken
together with the results that the cortical perimeter increased in both
the ALF and ELD groups, it is suggested that ELD was more effective
than ALF in countering endocortical bone resorption, thereby
maintaining cortical thickness. This is also consistent with the trend
for increased CSA by ELD. Fig. 4 schematically illustrates the distinct
actions of ELD and ALF on the cortical geometry and density of the
femoral neck and shaft.
As bone resorption accelerates with aging, especially from the
inner surface of the cortex, the endocortical compartment tends to
become trabeculated, and therefore represents an important target
site for intervention. A possible mechanism of action of ELD is to
reduce the number of pores opening through the endocortical surface,
therebymaintaining cortical thickness and increasing cortical density.
ALF treatment, on the other hand, failed to block the resorption of
trabeculated endocortical bone, resulting in an expansion of the
trabecular bone marrow cavity, decreased trabecular BMD, reduced
cortical thickness, and increased cortical density. As a result of the
ELD-speciﬁc effect on the endocortical surface, it is conceivable that
ELDwasmore effective in increasing cortical bonemass than ALF. This
observation is supported by the signiﬁcantly higher reduction of bone
resorption biomarkers observed with ELD treatment than with ALF
treatment (data not shown).
Regarding the increased cortical perimeter in both the ALF and ELD
groups, it is difﬁcult to determine whether this simply reﬂects the age-
related increase inperiosteal appositionorwhether thedrugs in fact had
somepositive effect in extendingboneperimeter. A recentQCT study on
2 years' treatment with teriparatide [18] failed to reveal increases in
total CSA or periosteal apposition. Although direct comparison is not
feasible, given the difference in the observation period (2 versus
3 years) and presumably also in the threshold value to deﬁne the
cortical bone, the signiﬁcant increases in cortical perimeter after 3 years'
treatmentwith ELD aswell as ALFmay imply that ELD and ALF have the
potential to stimulate bone apposition at the periosteal surface.
Along with these changes in the 3D geometry of the femoral neck,
ELD, but not ALF, improved biomechanical properties, speciﬁcally
CSMI and SM. In a previous study [26] we compared the features of the
femoral neck geometry in patients with hip or trochanteric fractures
with their controls; patients with femoral neck fracture had a
signiﬁcantly longer HAL, lower CSMI, and higher BR, while those
with trochanteric fracture had a smaller cortical CSA of the femoral
neck. In view of the present ﬁndings that ELD increases CSMI and
perhaps cortical CSA as well, ELD is expected to have the potential to
reduce the risk of both femoral neck and trochanteric fractures.
Fig. 4. Schematic illustration of the effects of eldecalcitol (ELD) vs. alfacalcidol (ALF) on the cortical geometry and density of the femoral neck and shaft. In the femoral neck,
compared with baseline, the effects of ALF and ELD on the cortical perimeter (i.e., periosteal apposition) are similar. However, ELD counters endocortical resorption more effectively
than ALF, which is reﬂected by the increased cortical thickness, thereby leading to improved biomechanical properties, represented by section modulus (SM). In the femoral shaft,
ALF and ELD have similar effects, except that ELD decreases cortical density less than ALF, and increases inner cortical perimeter less than ALF. SM: section modulus; BR: buckling
ratio; CSMI: cross-sectional moment of inertia.
333M. Ito et al. / Bone 49 (2011) 328–334ALF and ELD failed to decrease BR. BR is a secondary parameter
calculated by the average distance to the center of mass divided by
average cortical thickness, and it is employed as a means to estimate the
stability of the cortex in thin-walled regions subject to bending. Our
previous study [26], in which BR was calculated according to the same
formula, demonstrated that the BR in patients with hip fracture (12.22±
1.69) was higher than that in the control group (8.32±2.13). In the
present study, the percentage increase in BR during the 3-year follow-up
was smaller in the ELD group (0.48%/year; 8.92±2.18 at baseline and
9.21±2.28 at 144 weeks) than in the ALF group (2.55%/year; 9.21±2.36
at baseline and 9.90±2.71 at 144 weeks). In view of our previous results
on BR [25], calculated by the same formula, that the longitudinal change
in BR of healthy post-menopausal women younger than the subjects in
this study was 1.48±4.81% per year, it is tempting to speculate that ELD
may have countered the age-related increase in BR.
The bone geometry and vBMD of the femoral shaft were examined
using an analytical program different from that used to examine the
femoral neck. Although it is difﬁcult to compare values obtained using
different software, we reasoned that comparison of the results by the
percentage changes should be acceptable. T.AR and B.AR in the femoral
shaft correspond respectively to total and cortical CSAs of the femoral
neck, and OUT.PERI corresponds to cortical perimeter of the femoral
neck. The results (Fig. 3) indicate that the changes in geometry of the
femoral shaftwere very consistentwith the features in the femoral neck.
Total CSA of the femoral neck increased in both the ALF and ELD groups
(Fig. 1), as did T.AR of the femoral shaft (Fig. 3). B.AR of the femoral shaft
increased signiﬁcantly only in the ELD group (Fig. 3), and cortical CSA of
the femoral neck increased more in the ELD group (Fig. 1). OUT.PERI of
the femoral shaft increased in both the ALF and ELD groups (Fig. 3), as
did the cortical perimeter of the femoral neck (Fig. 1).
Notably, the cortical vBMD of the femoral neck increased in both the
ALF and ELD groups, whereas the cortical vBMD of the femoral shaft
decreased in both groups. Since the cortex in the femoral neck is very
thin compared to that in the shaft, the partial-volume effect should be
taken into account when evaluating the cortical vBMD of the femoral
neck. However, according to our previous study on age-related changes
in the femoral neck and shaft in non-osteoporotic subjects [25], the rateof decrease in cortical vBMDwas greater in the femoral shaft than in the
femoral neck. It is possible, therefore, that ALF and ELD failed to prevent
the rapid decline in cortical density of the femoral shaft.
Finally, the present study has limitations. First, the study lacked a
placebo group. Second, because our study included very few cases of
hip fracture (only one in each group), the relationship of ALF or ELD
treatment with the incidence of hip fracture has not been veriﬁed.
In conclusion, our longitudinal analysis of hip geometry by clinical CT
has revealed the advantage of ELD over ALF in maintaining cortical
thickness and vBMD of the femoral neck and shaft, probably through
mitigating endocortical bone resorption, thereby improving the
biomechanical parameters. By maintaining the biomechanical proper-
ties of the proximal femur, ELDmayhave thepotential to reduce the risk
of hip fracture.
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334 M. Ito et al. / Bone 49 (2011) 328–334Appendix A. CT scanners and their scanning condition.CT scanner X-ray energy X-ray current Rotation speed Beam pitch FOV Slice thickness Recontruction
image thickness
Recontruction
ﬁlter
(kV) (mA) (sec/rot) (mm) (mm) (mm)
Toshiba Aquillion 64 120 230 1.0 0.9375 350 1.00 0.500 FC30
Aquillion 16 120 230 1.0 0.9375 350 1.00 0.500 FC30
Aquillion 4 120 200~230 1.0 0.875 350 1.00 0.500 FC30
Asteion 4 120 200~230 1.0 0.875 350 1.00 0.500 FC30
GE-Yokogawa lightSpeed Ultra_16 120~140 300 0.8 0.5625 350 1.25 0.625 Bone
lightSpeed Ultra_8 120~140 300 0.8 0.625 350 1.25 0.625 Bone
lightSpeed Plus_4 120~140 300 0.8 0.75 350 1.25 0.625 Bone
Siemens Somatom plus4Volume Zoom 140 230 1.0 1.25 350 1.00 0.500 B80
FOV: Field of view.References
[1] Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis
impact. Arch Intern Med 1991;151:2026–32.
[2] Orimo H, Hashimoto T, Sakata K, Yoshimura N, Suzuki T, Hosoi T. Trends in the
incidence of hip fracture in Japan, 1987–1997: the third nationwide survey. J Bone
Miner Metab 2000;18:126–31.
[3] Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R. Sequential change
in quality of life for patients with incident clinical fractures: a prospective study.
Osteoporos Int 2009;20:695–702.
[4] Ito M. Recent progress in bone imaging for osteoporosis research. J Bone Miner
Metab 2011;29:131–40.
[5] Yoshikawa T, Turner CH, PeacockM, Slemenda CW,Weaver CM, Teegarden D, et al.
Geometric structure of the femoral neck measured using dual-energy x-ray
absorptiometry. J Bone Miner Res 1994;9:1053–64.
[6] Beck TJ, Ruff CB, Warden KE, Scott Jr WW, Rao GU. Predicting femoral neck strength
from bone mineral data. A structural approach. Invest Radiol 1990;25:6–18.
[7] Rivadeneira F, Zillikens MC, De Laet CEDH, Hofman A, Uitterlinden AG, Beck TJ,
et al. Femoral neck BMD is a strong predictor of hip fracture susceptibility in
elderly men andwomen because it detects cortical bone instability: the Rotterdam
Study. J Bone Miner Res 2007;22:1781–90.
[8] Kaptoge S, Beck TJ, Reeve J, Stone KL, Hillier TA, Cauley JA, et al. Prediction
of incident hip fracture risk by femur geometry variables measured by hip
structural analysis in the study of osteoporotic fractures. J Bone Miner Res 2008;23:
1892–904.
[9] Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, et al.
Effects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the
proximal femur in elderly osteoporotic women. Bone 2005;36:948–58.
[10] Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, et al.
Structural effects of raloxifene on the proximal femur: results from the multiple
outcomes of raloxifene evaluation trial. Osteoporos Int 2006;17:575–86.
[11] Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE. DXA-based hip
structural analysis of once-weekly bisphosphonate-treated postmenopausal
women with low bone mass. Osteoporos Int 2009;20:911–21.
[12] Ito M, Sone T, Fukunaga M. Effect of minodronic acid hydrate on hip geometry in
Japanese women with postmenopausal osteoporosis. J Bone Miner Metab 2010;28:
334–41.
[13] Nakamura T, Turner CH, Yoshikawa T, Slemenda CW, Peacock M, Burr DB, et al. Do
variations in hip geometry explain differences in hip fracture risk between
Japanese and white Americans? J Bone Miner Res 1994;9:1071–6.[14] Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year
of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N
Engl J Med 2005;353:555–65.
[15] Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The
effects of parathyroid hormone and alendronate alone or in combination in
postmenopausal osteoporosis. N Engl J Med 2003;349:1207–15.
[16] Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A. Cortical and trabecular bone
mineral loss from the spine and hip in long-duration spaceﬂight. J Bone Miner Res
2004;19:1006–12.
[17] Riggs BL, Melton III LJ, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, et al. Population-
based study of age and sex differences in bone volumetric density, size, geometry,
and structure at different skeletal sites. J Bone Miner Res 2004;19:1945–54.
[18] Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC. Quantitative computed
tomographic assessment of the effects of 24 months of teriparatide treatment on
3D femoral neck bone distribution, geometry, and bone strength: results from the
EUROFORS study. J Bone Miner Res 2010;25:472–81.
[19] Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, et al. A new
active vitamin D, ED-71, increases bone mass in osteoporotic patients under
vitamin D supplementation: a randomized, double-blind, placebo-controlled
clinical trial. J Clin Endocrinol Metab 2005;90:5031–6.
[20] Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, et al. A new active
vitamin D compound, eldecalcitol, is superior to alfacalcidol in preventing
fractures in osteoporotic patients. J Bone Miner Res 2010;25(Suppl 1):s78.
[21] Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, et al. Effects of 1
alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures
in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370–6.
[22] Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, et al. A comparison of
alfacalcidol and menatetrenone for the treatment of bone loss in an ovariecto-
mized rat model of osteoporosis. Calcif Tissue Int 2002;71:69–79.
[23] Shiraishi A, Ito M, Hayakawa N, Kubota N, Kubodera N, Ogata E. Calcium
supplementation does not reproduce the pharmacological efﬁcacy of alfacalcidol
for the treatment of osteoporosis in rats. Calcif Tissue Int 2006;78:152–61.
[24] OrimoH, Hayashi Y, FukunagaM, Sone T, Fujiwara S, ShirakiM, et al. Diagnostic criteria
for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001;19:331–7.
[25] Ito M, Nakata T, Nishida A, Uetani M. Age-related changes in bone density,
geometry, and biomechanical properties of the proximal femur: CT-based 3D hip
structure analysis in normal postmenopausal women. Bone 2011;48:627–30.
[26] Ito M, Wakao N, Hida T, Matsui Y, Abe Y, Aoyagi K, et al. Analysis of hip geometry
by clinical CT for the assessment of hip fracture risk in elderly Japanese women.
Bone 2010;46:453–7.
